Search results
Results from the WOW.Com Content Network
Pfizer posted strong earnings in the third quarter as investors worry about the stock's value. ... Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma ...
Pfizer’s stock hit an all-time high of $61.25 in December 2021 as its COVID shot, as well as its antiviral treatment Paxlovid, helped billions return to work, school, and public life.
Bourla said that given the efforts made in the past year to help boost Pfizer's stock, ... Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance ...
Pfizer (NYSE: PFE) stock investors are curious about the valuation and prospects for the healthcare company. Stock prices used were the afternoon prices of Jan. 1, 2025. The video was published on ...
One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent years due to its COVID-19 vaccine and pill (its revenue topped $100 ...
Pfizer's stock was down 2% in early trading Thursday. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs ...
PFE Revenue (TTM) data by YCharts Pfizer's vaccine (Comirnaty) and treatment option (Paxlovid) combined for $56 billion in revenue in 2022. Those two products represented just $2.4 billion of ...
Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is $1.55. Pfizer Just Reassured Investors, but Is the Stock a Buy? Skip to ...